Compare Charles River Laboratories Intl. Inc (CRL) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Zscaler Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while Zscaler Inc trades at $234 (market cap $35.35B). The key difference: Zscaler Inc is far larger — about 2.5× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Zscaler Inc for 41 Days on average.
| CRL | ZS | |
|---|---|---|
Market Cap | $14.23B | $35.35B |
Volume | 1,176,885 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $310.77 | $336.27 |
52-Week Low | $149.93 | $118.05 |
Typical Hold Time | 33 Days | 41 Days |
Enterprise Value | $17.06B | $33.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
Zscaler (ZS) trades at $233.73, up 9.45% today, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. Revenue growth is robust, rising from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net margin of -1.88%. Recent news includes a CRO transition and an upcoming Investor Day, while analyst sentiment is overwhelmingly positive with 79.6% buy ratings.
The stock offers growth potential driven by cybersecurity demand and AI product adoption, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target of $222.83 suggests modest downside from current levels, requiring careful risk assessment amid volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
